Do analysts prefer FONR or CODX?

Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 1,098.93%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, FONR or CODX?

Fonar has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fonar $104.35M 1.13 $8.33M $1.00 19.09 Co-Diagnostics $620K 33.51 -$46.90M -$15.77 N/A

Is FONR or CODX more profitable?

Fonar has a net margin of 6.35% compared to Co-Diagnostics' net margin of -6,760.63%. Fonar's return on equity of 4.12% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Fonar 6.35% 4.12% 3.07% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media favor FONR or CODX?

In the previous week, Fonar had 5 more articles in the media than Co-Diagnostics. MarketBeat recorded 7 mentions for Fonar and 2 mentions for Co-Diagnostics. Fonar's average media sentiment score of 1.18 beat Co-Diagnostics' score of 0.28 indicating that Fonar is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fonar 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NYXH or CODX more profitable?

Nyxoah has a net margin of -543.21% compared to Co-Diagnostics' net margin of -6,760.63%. Nyxoah's return on equity of -163.73% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media prefer NYXH or CODX?

In the previous week, Nyxoah had 4 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for Nyxoah and 2 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.28 beat Nyxoah's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CODX or IINN?

Co-Diagnostics currently has a consensus target price of $67.50, suggesting a potential upside of 1,098.93%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CODX or IINN?

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Co-Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Co-Diagnostics $620K 33.51 -$46.90M -$15.77 N/A Inspira Technologies OXY B.H.N. $289K 232.61 -$13.22M N/A N/A

Does the media refer more to CODX or IINN?

In the previous week, Co-Diagnostics and Co-Diagnostics both had 2 articles in the media. Co-Diagnostics' average media sentiment score of 0.28 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CODX or QTEX?

Co-Diagnostics currently has a consensus price target of $67.50, indicating a potential upside of 1,098.93%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CODX or QTEX?

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Co-Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Co-Diagnostics $620K 33.51 -$46.90M -$15.77 N/A Inspira Technologies OXY B.H.N. $290K 176.03 -$13.22M N/A N/A

Does the media favor CODX or QTEX?

In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 3 mentions for Inspira Technologies OXY B.H.N. and 2 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.28 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Co-Diagnostics (CODX) Competitors

$5.63 -0.13 (-2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$5.75 +0.12 (+2.13%)

As of 07:59 PM Eastern

Compare

CODX vs. FONR, NYXH, VANI, IINN, and QTEX

Should you buy Co-Diagnostics stock or one of its competitors? MarketBeat compares Co-Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Co-Diagnostics include Fonar (FONR), Nyxoah (NYXH), Vivani Medical (VANI), Inspira Technologies OXY B.H.N. (IINN), and Inspira Technologies OXY B.H.N. (QTEX). These companies are all part of the "medical equipment" industry.

How does Co-Diagnostics compare to Fonar?

Fonar (NASDAQ:FONR) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

50.6% of Fonar shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 7.9% of Fonar shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Fonar has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.13	$8.33M	$1.00	19.09
Co-Diagnostics	$620K	33.51	-$46.90M	-$15.77	N/A

Fonar has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market.

Fonar has a net margin of 6.35% compared to Co-Diagnostics' net margin of -6,760.63%. Fonar's return on equity of 4.12% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

In the previous week, Fonar had 5 more articles in the media than Co-Diagnostics. MarketBeat recorded 7 mentions for Fonar and 2 mentions for Co-Diagnostics. Fonar's average media sentiment score of 1.18 beat Co-Diagnostics' score of 0.28 indicating that Fonar is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fonar	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 1,098.93%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Fonar beats Co-Diagnostics on 11 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

15.0% of Co-Diagnostics shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nyxoah has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

Nyxoah currently has a consensus price target of $7.67, indicating a potential upside of 428.74%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 1,098.93%. Given Co-Diagnostics' higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nyxoah had 4 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for Nyxoah and 2 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.28 beat Nyxoah's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nyxoah has a net margin of -543.21% compared to Co-Diagnostics' net margin of -6,760.63%. Nyxoah's return on equity of -163.73% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Co-Diagnostics has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.96	-$101.92M	-$2.48	N/A
Co-Diagnostics	$620K	33.51	-$46.90M	-$15.77	N/A

Summary

Nyxoah beats Co-Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to Vivani Medical?

Co-Diagnostics (NASDAQ:CODX) and Vivani Medical (NASDAQ:VANI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Vivani Medical has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Vivani Medical	N/A	-264.04%	-79.85%

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vivani Medical has lower revenue, but higher earnings than Co-Diagnostics. Vivani Medical is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	33.51	-$46.90M	-$15.77	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

Co-Diagnostics has a beta of 2.74, meaning that its share price is 174% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 1,098.93%. Vivani Medical has a consensus target price of $3.50, indicating a potential upside of 196.61%. Given Co-Diagnostics' higher possible upside, equities analysts clearly believe Co-Diagnostics is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Co-Diagnostics had 2 more articles in the media than Vivani Medical. MarketBeat recorded 2 mentions for Co-Diagnostics and 0 mentions for Vivani Medical. Co-Diagnostics' average media sentiment score of 0.28 beat Vivani Medical's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Co-Diagnostics	Neutral
Vivani Medical	Neutral

Summary

Co-Diagnostics beats Vivani Medical on 8 of the 13 factors compared between the two stocks.

How does Co-Diagnostics compare to Inspira Technologies OXY B.H.N.?

Co-Diagnostics (NASDAQ:CODX) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Co-Diagnostics and Co-Diagnostics both had 2 articles in the media. Co-Diagnostics' average media sentiment score of 0.28 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Co-Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	33.51	-$46.90M	-$15.77	N/A
Inspira Technologies OXY B.H.N.	$289K	232.61	-$13.22M	N/A	N/A

Co-Diagnostics has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

Co-Diagnostics currently has a consensus target price of $67.50, suggesting a potential upside of 1,098.93%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Co-Diagnostics beats Inspira Technologies OXY B.H.N. on 7 of the 13 factors compared between the two stocks.

How does Co-Diagnostics compare to Inspira Technologies OXY B.H.N.?

Co-Diagnostics (NASDAQ:CODX) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 5.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Co-Diagnostics currently has a consensus price target of $67.50, indicating a potential upside of 1,098.93%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 3 mentions for Inspira Technologies OXY B.H.N. and 2 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.28 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Co-Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	33.51	-$46.90M	-$15.77	N/A
Inspira Technologies OXY B.H.N.	$290K	176.03	-$13.22M	N/A	N/A

Co-Diagnostics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.11, suggesting that its share price is 311% more volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.23M	$8.71B	$6.44B	$11.97B
Dividend Yield	N/A	1.79%	2.69%	5.32%
P/E Ratio	-0.36	22.29	23.77	23.66
Price / Sales	33.51	21.75	488.50	86.29
Price / Cash	N/A	88.38	41.39	55.53
Price / Book	0.62	5.76	9.76	6.39
Net Income	-$46.90M	$175.77M	$3.56B	$337.36M
7 Day Performance	-34.00%	-2.19%	-3.19%	-3.07%
1 Month Performance	254.09%	7.78%	-0.11%	0.37%
1 Year Performance	-38.31%	5.10%	25.29%	27.87%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	2.0102 of 5 stars	$5.63 -2.3%	$67.50 +1,098.9%	-33.5%	$21.23M	$620K	N/A	100	Gap Down
FONR Fonar	3.0172 of 5 stars	$19.12 +0.0%	N/A	N/A	$117.90M	$104.35M	19.12	480	Positive News Insider Trade
NYXH Nyxoah	1.8426 of 5 stars	$2.97 -1.8%	$7.67 +158.4%	-62.7%	$115.51M	$11.33M	N/A	110	News Coverage Gap Down Trading Halted
VANI Vivani Medical	2.267 of 5 stars	$1.30 +0.8%	$3.50 +169.2%	+14.3%	$113.83M	N/A	N/A	20	Positive News
IINN Inspira Technologies OXY B.H.N.	0.8765 of 5 stars	$3.08 +0.3%	N/A	+252.3%	$110.72M	$289K	N/A	20	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. FONR, NYXH, VANI, IINN, and QTEX

How does Co-Diagnostics compare to Fonar?

Summary

How does Co-Diagnostics compare to Nyxoah?

Summary

How does Co-Diagnostics compare to Vivani Medical?

Summary

How does Co-Diagnostics compare to Inspira Technologies OXY B.H.N.?

Summary

How does Co-Diagnostics compare to Inspira Technologies OXY B.H.N.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. FONR, NYXH, VANI, IINN, and QTEX

How does Co-Diagnostics compare to Fonar?

Do insiders & institutionals hold more shares of FONR or CODX?

Which has stronger valuation and earnings, FONR or CODX?

Which has more risk and volatility, FONR or CODX?

Is FONR or CODX more profitable?

Does the media favor FONR or CODX?

Do analysts prefer FONR or CODX?

Summary

How does Co-Diagnostics compare to Nyxoah?

Do institutionals and insiders believe in NYXH or CODX?

Which has more volatility & risk, NYXH or CODX?

Do analysts recommend NYXH or CODX?

Does the media prefer NYXH or CODX?

Is NYXH or CODX more profitable?

Which has stronger valuation and earnings, NYXH or CODX?

Summary

How does Co-Diagnostics compare to Vivani Medical?

Is CODX or VANI more profitable?

Do institutionals & insiders believe in CODX or VANI?

Which has preferable valuation and earnings, CODX or VANI?

Which has more volatility and risk, CODX or VANI?

Do analysts recommend CODX or VANI?

Does the media refer more to CODX or VANI?

Summary

How does Co-Diagnostics compare to Inspira Technologies OXY B.H.N.?

Do institutionals and insiders have more ownership in CODX or IINN?

Does the media refer more to CODX or IINN?

Is CODX or IINN more profitable?

Which has stronger valuation & earnings, CODX or IINN?

Which has more volatility and risk, CODX or IINN?

Do analysts rate CODX or IINN?

Summary

How does Co-Diagnostics compare to Inspira Technologies OXY B.H.N.?

Do institutionals & insiders have more ownership in CODX or QTEX?

Do analysts prefer CODX or QTEX?

Does the media favor CODX or QTEX?

Is CODX or QTEX more profitable?

Which has better valuation and earnings, CODX or QTEX?

Which has more risk and volatility, CODX or QTEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools